The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; emd serono; Jazz Pharmaceuticals; Merck; novartis; nuvation bio; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Ernest Nadal
Honoraria - Apollomics; Roche/Genentech; Transgene
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Genmab; Janssen Oncology; Lilly; Merck Serono; MSD; Pfizer; Pierre Fabre; Qiagen; Roche; Sanofi; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Takeda
 
Shobhit Baijal
Honoraria - Abbvie; Agilent; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; FoundationOne; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi and Takeda; SERVIER
 
Alessandra Bulotta
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Regeneron
 
Christina Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Natera; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); TP Therapeutics (Inst)
 
Holger Thurm
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Anna Polli
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda